Security Reports > Alnylam Pharmaceuticals

Alnylam Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report  ᛫  Biotech & Pharmaceuticals
Last updated September 25, 2020

Alnylam Pharmaceuticals Security Rating

/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Alnylam Pharmaceuticals is implementing good security practices.

Company Information


About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Data Breaches and Security News

Security Report for Alnylam Pharmaceuticals

Want a security rating for your organization?

This report shows a preliminary security rating for Alnylam Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Alnylam Pharmaceuticals's security performance with other companies